Aboleris Pharma (FR)

https://www.aboleris-pharma.com

AbolerIS Pharma is a pioneering biopharmaceutical company focused on revolutionizing immunotherapy for autoimmune and inflammatory diseases. Through innovative antibody therapy targeting CD45RC, AbolerIS Pharma aims to restore immune balance and achieve long-lasting remission for patients with conditions such as rheumatoid arthritis. Led by a team of reputable scientists, AbolerIS Pharma translates groundbreaking discoveries into tangible therapies, with an unwavering dedication to addressing patients’ needs. *

	Start	2023-09-21 existent
	Predecessor	University of Nantes (Université de Nantes)
	Industry	BIOTECH
	Industry 2	anti-CD45RC antibody

	Region	Nantes
	Country	France
	Street	1 Rue Gaston Veil
	City	44000 Nantes
		Address record changed: 2023-09-23

Basic data	Employees	n. a.

		* Document for »About Section«: Aboleris Pharma. (9/18/23). "Press Release: Aboleris Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases". Gosselies.

		Record changed: 2024-02-12

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Aboleris Pharma (Group)

[1] Aboleris Pharma. (9/18/23). "Press Release: Aboleris Pharma Announces €27 Million in Series A Financing to Advance its Novel Treatment Paradigm for Autoimmune and Inflammatory Diseases". Gosselies....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)